The impetus for EPIC is an earlier study sponsored by Boehringer Ingelheim called QUEST (Quality of Life and Extension of Survival Time). At the time, it was the largest clinical study of its kind conducted among dogs with CHF due to MMVD. This international, multi-center trial compared the effects of two different treatments. QUEST established pimobendan as the reference treatment for dogs with CHF caused by MMVD.
One key question was left unanswered: Can pimobendan also delay the onset of signs of congestive heart failure? EPIC, which is even more comprehensive, will seek the answer.
For more information about QUEST, please visit www.questtrial.com.
Professor Jens Häggström
Swedish University of Agricultural Sciences
Faculty of Veterinary Medicine and Animal Science
Uppsala, Sweden
